Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 66Neoplasms 49Stomach Neoplasms 45Colorectal Neoplasms 42Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 30Uterine Cervical Neoplasms 28Rectal Neoplasms 28Carcinoma, Hepatocellular 25Prostatic Neoplasms 24Recurrence 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 18Neoplasm Metastasis 16Colonic Neoplasms 16Esophageal Neoplasms 15Urinary Bladder Neoplasms 14Thyroid Neoplasms 14Pancreatic Neoplasms 14Nasopharyngeal Carcinoma 14Leukemia, Myeloid, Acute 13Head and Neck Neoplasms 13Small Cell Lung Carcinoma 11Papillomavirus Infections 11Multiple Myeloma 11Motor Activity 11Melanoma 11Lymphoma 11Sarcoma 10Lymphoma, Non-Hodgkin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Subcutaneous panniculitis-like T-cell lymphoma × Clear all
NCT02533700 2020-03-10

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

Shandong Provincial Hospital

Phase 2 Unknown
106 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡